Name: Stryker Mako (Mako 4 SmartRobotics)
Brand: Stryker

Who's exposed

Deployment status

Mako is the most-deployed robot in orthopedic surgery. Stryker reported more than 1.5 million Mako procedures performed across 45 countries as of its AAOS 2025 announcement — a fleet built up since the platform's early total-knee days that now spans total knee, total hip, partial knee, and spine. The current fourth-generation Mako 4 is a single multi-specialty system. In February 2026 Stryker opened a second front: the Mako RPS, a handheld robotic system for total knee, entered limited U.S. release and completed its first cases — aimed explicitly at ambulatory surgery centers and at surgeons who never adopted the full robotic-arm cart. A shoulder application, in limited launch on the prior generation, is slated to reach Mako 4 in mid-2026. This is a mature, at-scale surgical platform, not an experiment.

When this hits the labor market

Mako does not replace the orthopedic surgeon — the same call we make on every surgical robot in this catalog. What robotic-arm-assisted joint replacement changes is throughput and standardization: it narrows the variability between surgeons, shortens the learning curve on a given procedure, and lets a hospital or surgery center push more knees and hips through the same headcount. The Mako RPS handheld extends that reach from the hospital cart down into the outpatient surgery center, where cost pressure is sharpest. The labor effect is second-order and slow — not layoffs, but slower growth in surgeon headcount relative to procedure volume, a shrinking premium on the manual-technique virtuoso, and an OR workflow that surgical techs and device reps must relearn with each generation. The job titles persist; the leverage inside them shifts toward whoever owns the platform.

The most-deployed robot in the operating room

Most of the surgical robots people know about work in soft tissue — the da Vinci lineage that this catalog already covers. Mako is the other story. It is a robotic arm for orthopedics: joint replacement, where the work is cutting and shaping bone to a plan, and where a machine that holds a hard boundary has an obvious edge over a free human hand. Stryker’s headline number, from its AAOS 2025 meeting, is 1.5 million Mako procedures performed across 45 countries. That is not a launch metric. It is an installed base doing daily volume, across total knee, total hip, partial knee, and now spine.

That scale is why Mako earns a catalog entry even though surgical robotics is not a job-elimination story. It is the clearest evidence in the operating room of what robotic assistance actually does to the economics of a skilled trade — and it just expanded its footprint.

Mako 4, and now a handheld

The current generation, Mako 4, is a single system that runs multiple specialties from one arm — the consolidation play, fewer machines covering more procedures. Then in February 2026 Stryker did something more interesting: it launched the Mako RPS, a handheld robotic system for total knee replacement, in limited U.S. release, and started its first cases.

The handheld matters because of where it is aimed. The full Mako arm is a big capital purchase that lives in a hospital. The RPS is built for the ambulatory surgery center and for the surgeons who resisted the cart — a smaller, cheaper form of the same robotic guidance, pushed into the outpatient setting where more and more joint replacements are heading and where cost discipline is tightest. A shoulder application is due on Mako 4 by mid-2026. The platform is not just deployed; it is still spreading.

Why we care for LostJobs

Mako does not take a surgeon’s job, and we say so plainly — the same read we gave da Vinci and Versius. What it does is quieter and, over time, larger. Robotic-arm assistance compresses the gap between the best surgeon in the region and the average one: the plan is templated, the cut is bounded, the learning curve flattens. A hospital that once needed the manual virtuoso can now get a reliable result from a broader bench, and can run more cases through the same number of surgeons.

The labor consequence is not a layoff notice; it is a slope change. Surgeon headcount grows more slowly than procedure volume. The premium that used to attach to rare manual skill erodes as the platform standardizes the outcome. And every hardware generation forces the scrub techs, nurses, and device reps around the table to rebuild the workflow and re-earn their fluency. The title survives; the leverage inside it moves toward Stryker. When the machine that shapes the outcome is owned by the vendor, the vendor is quietly in the room during every compensation and staffing decision that follows.